SCHEMBL5146976

SCHEMBL5146976

CC(O)Cc1ccnc(Br)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 4/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ AR P10275 4/20 0.33
▸ LOX P28300 1/20 0.33
▸ LOXL2 Q9Y4K0 1/20 0.33
▸ GABRA1 P14867 1/20 0.33
▸ GABRB2 P47870 1/20 0.33
▸ NOS2 P35228 2/20 0.33
▸ RECQL P46063 3/20 0.32
▸ ALOX15 P16050 3/20 0.32
▸ ALOX12 P18054 3/20 0.32
▸ KDM4E B2RXH2 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ ESR1 P03372 2/20 0.32
▸ TP53 P04637 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ MAPK1 P28482 2/20 0.32
▸ KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30741537 1.00 NR3C2 (0.35) NR3C2PARP1ARLOXLOXL2
SCHEMBL31440248 0.86 PARP1 (0.36) NR3C2PARP1ARLOXLOXL2
SCHEMBL17000172 0.85 GABRA1 (0.40) NR3C2PARP1ARLOXLOXL2
SCHEMBL15911399 0.81 PNMT (0.46) SLC6A2HTR2AHTR2BSLC6A3
SCHEMBL12633376 0.78 NOS2 (0.58) NR3C2GABRA1GABRB2NOS2KDM4E
SCHEMBL25305878 0.77 KDM6B (0.51) NR3C2PARP1ARGABRA1GABRB2
SCHEMBL29183400 0.76 AR (0.33) PARP1ARLOXLOXL2
SCHEMBL29183405 0.76 AR (0.33) PARP1ARLOXLOXL2
SCHEMBL18674835 0.75 NR3C2 (0.34) NR3C2ALOX12KDM4EALOX5
SCHEMBL648113 0.74 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103145747-A Polysubstituted derivatives of 6-heteroarylimidazo [1,2-a ] pyridines, process for their preparation and their therapeutic use SANOFI AVENTIS 2013-06-12 — — CN disclosed
CN-102036989-A Polysubstituted derivatives of 6-heteroarylimidazo [1,2-a ] pyridines, process for their preparation and their therapeutic use SANOFI AVENTIS 2011-04-27 — — CN disclosed
EP-1562588-A4 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO INC (US) 2007-10-31 — — EP disclosed
EP-1592419-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION Merck Frosst Canada & Co. (CA) 2005-11-09 — — EP disclosed
EP-1565466-A2 METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 Merck & Co., Inc. (US) 2005-08-24 — — EP disclosed
EP-1562588-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS Merck & Co., Inc. (US) 2005-08-17 — — EP disclosed
EP-1436290-A1 ALKYNE-ARYL-NAPHTHYRIDIN-4(1H)-0NE DERIVATIVES AS TYPE IV PHOSPHODIESTERASE INHIBITOR Merck Frosst Canada & Co. (CA) 2004-07-14 — — EP disclosed
WO-2004048377-A2 METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4 MERCK & CO., INC. (US) 2004-06-10 — — WO disclosed
WO-2004047836-A1 USE OF PHOSPHODIESTERASE-4 INHIBITORS AS ENHANCERS OF COGNITION MERCK FROSST CANADA & CO. (CA) 2004-06-10 — — WO disclosed
WO-2004045508-A2 USE OF PDE4 INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS MERCK & CO., INC. (US) 2004-06-03 — — WO disclosed
EP-1397359-A1 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS Merck Frosst Canada & Co. (CA) 2004-03-17 — — EP disclosed
WO-2003018579-A1 ALKYNE-ARYL PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2003-03-06 — — WO disclosed
WO-2002094823-A1 1-BIARYL-1,8-NAPTHYRIDIN-4-ONE PHOSPHODIESTERASE-4 INHIBITORS MERCK FROSST CANADA & CO. (CA) 2002-11-28 — — WO disclosed
Send feedback